Ambee Pharmaceuticals Plc

AMBEEPHA

BD0451AMBPH6

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 03:30:00 21/05/2024 am IST			5-day change	1st Jan Change
715.3 ^BDT	-0.68%		-0.03%	-12.30%

06/02	Ambee Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Ambee Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the First Quarter Ended September 30, 2017

November 13, 2017

Ambee Pharmaceuticals Ltd. announced unaudited earnings results for the first quarter ended September 30, 2017. For the quarter, the company reported EPS was BDT 0.75 as against BDT 0.55 a year ago. NOCFPS was BDT 3.45 as against BDT 3.35 a year ago. NAV per share was BDT 25.99 as on September 30, 2017 and BDT 25.24 as on June 30, 2017.

Latest news about Ambee Pharmaceuticals Plc

Ambee Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	06/02	CI
Ambee Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Ambee Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023	05/11	CI
Ambee Pharmaceuticals Ltd. will Change its Name to Ambee Pharmaceuticals PLC	09/23/09	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	10/23/10	CI
Ambee Pharmaceuticals Limited Appoints Mohammad Amir Hossain as Company Secretary	03/23/03	CI
Ambee Pharmaceuticals Limited Appoints Khairul Aziz as Chief Financial Officer	27/23/27	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	14/23/14	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	10/22/10	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	27/22/27	CI
Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022	22/22/22	CI
Ambee Pharmaceuticals Limited Appoints Ms. Kazi Tanzzina Ferdous as Managing Director	12/22/12	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2021	14/21/14	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Year Ended on June 30, 2020	08/21/08	CI
Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2020	08/21/08	CI
Ambee Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2019	27/19/27	CI
Ambee Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2018	13/18/13	CI
Ambee Pharmaceuticals Ltd. Reports Earnings Results for the Year Ended June 30, 2018	13/18/13	CI
Ambee Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 2018	25/18/25	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Financial Results for the Quarter and Six Months Ended December 31, 2017	29/18/29	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the First Quarter Ended September 30, 2017	13/17/13	CI
Ambee Pharmaceuticals Ltd Recommends 30% Cash Dividend for the Year Ended on June 30, 2017	06/17/06	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2017	26/17/26	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2016	31/17/31	CI
Ambee Pharmaceuticals Ltd. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012	16/12/16	CI

Chart Ambee Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Ambee Pharmaceuticals Limited is a Bangladesh-based company, which is engaged in pharmaceutical operations. The principal activities of the Company are to manufacture, buy, sell, export, or otherwise deal in all kinds of drugs, medicines, pharmaceuticals, chemicals, medical or any other preparations and to refine, manipulate, or treat all such substances used in the pharmaceutical industry and to do all such acts necessary in connection with any business or chemist druggist, chemical and medicine manufactures, and pharmacists. Its products include ANTAC, AMBEECLOX, STOMACID, FLUXIN, MYCEF, A-ROX, MYZID, HIFLOX, HIFLOX-XR, LEXLO, TETRAM, DOXILLIN, TACTIN, NALIDEX, AFLUZOLE, KLION, AFUVIN, TRIBEN-DS, AMETROL-VT, MESPA, SURAL, TRIBEN, AMINOPHYLLINE, CODEX, NILKOF, DEXTROMETHORPHAN, AMBEECAL, ACES PLUS, CALCITATE, C-BON, AMBEECAL D, CALCIUM AMBEE, VITEX, FOLAC, VITEX GOLD, AROLAK, HITFLAM, NAPROXIN, FUNGAKIL, CINON, NOSTIS, AMASON, NOCTIN, DIPHEDAN, DOPEGYT, among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
AMBEE PHARMACEUTICALS PLC	-12.30%	14.64M
OTSUKA HOLDINGS CO., LTD.	+17.79%	22.02B
SANDOZ GROUP AG	+19.81%	15.08B
CIPLA LIMITED	+19.64%	14.37B
ZYDUS LIFESCIENCES LIMITED	+58.05%	13.06B
ONO PHARMACEUTICAL CO., LTD.	-9.70%	6.75B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.66%	5.64B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+4.00%	4.66B